The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Large Will The In-vitro Colorectal Cancer Screening Tests Market Be By 2030 Compared To Its 2026 Market Size?
The market size for in-vitro colorectal cancer screening tests has experienced significant growth in recent years. It is anticipated to increase from $1.3 billion in 2025 to $1.4 billion in 2026, at a compound annual growth rate (CAGR) of 7.7%. This historic expansion can be attributed to factors such as rising colorectal cancer incidence rates, the broadening of population screening programs, increased awareness regarding early cancer detection, the availability of laboratory-based diagnostic infrastructure, and improvements in biomarker identification.
The market for in-vitro colorectal cancer screening tests is projected to experience substantial expansion over the upcoming years. This market is set to reach a valuation of $1.82 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.8%. Several factors are driving this anticipated growth, including a greater embrace of tailored screening methods, a surge in demand for convenient at-home diagnostic options, the broadening scope of preventive healthcare programs, the increasing application of AI in result analysis, and a heightened emphasis on economical cancer screening solutions. Key trends foreseen during this period involve the wider acceptance of non-invasive screening techniques, increased utilization of multi-target stool DNA tests, the deeper incorporation of blood-based biomarker assays, the proliferation of kits for home sample collection, and a sharper focus on detecting cancer early in individuals without symptoms.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27319&type=smp
What Significant Factors Are Influencing The In-vitro Colorectal Cancer Screening Tests Market Expansion?
An anticipated boost to the in vitro colorectal cancer screening tests market is projected due to the increasing incidence of colorectal cancer. Colorectal cancer, a malignancy originating in the colon or rectum, frequently evolves from precancerous polyps. This growing prevalence is linked to unhealthy lifestyle choices, where factors such as inadequate diet, insufficient physical activity, and obesity heighten the likelihood of polyp formation and subsequent cancer development. In-vitro colorectal cancer screening tests assist in diagnosing the condition through non-invasive techniques capable of identifying early indicators of the disease. These tests enhance diagnostic precision by utilizing advanced biomarker detection, which facilitates earlier intervention and improves patient results. For example, the American Cancer Society, a US-based nonprofit, reported an estimated 154,270 new cases of colorectal cancer in February 2025, representing an increase from 152,810 cases recorded in 2024. Consequently, the expanding occurrence of colorectal cancer is a key factor propelling the expansion of the in vitro colorectal cancer screening tests market.
Which Segment Types Are Examined In The In-vitro Colorectal Cancer Screening Tests Market Segment Study?
The in-vitro colorectal cancer screening tests market covered in this report is segmented –
1) By Test Type: Fecal Occult Blood Test, Stool Deoxyribonucleic Acid Test, Blood Biomarker Test, Other Test Types
2) By Imaging Type: In-vitro Confirmatory Diagnostics, Laboratory-Based Molecular Testing, Companion Diagnostic Testing, Genetic And Epigenetic Testing, Biomarker Validation Testing, Risk Stratification Assays
3) By Application: Screening, Diagnosis, Monitoring, Risk Assessment, Post-Treatment Surveillance
4) By End User: Hospitals, Diagnostic Laboratories, Outpatient Clinics, Home Care Settings, Research Institutions
Subsegments:
1) By Fecal Occult Blood Test: Guaiac Based Fecal Occult Blood Test, Immunochemical Fecal Occult Blood Test
2) By Stool Deoxyribonucleic Acid Test: Single Target Stool Deoxyribonucleic Acid Test, Multi Target Stool Deoxyribonucleic Acid Test
3) By Blood Biomarker Test: Methylated Septin 9 Deoxyribonucleic Acid Test, Circulating Tumor Deoxyribonucleic Acid Test, Protein Biomarker Based Blood Test
4) By Other Test Types: Urine Based Biomarker Test, Serum Based Biomarker Test, Breath Based Volatile Organic Compound Test
What Trends Are Affecting The Direction Of The In-vitro Colorectal Cancer Screening Tests Market?
Companies operating within the in vitro colorectal cancer screening tests market are concentrating on the development of advanced diagnostic solutions, such as multi-target stool DNA tests, to enhance early detection accuracy, improve patient convenience, and decrease colorectal cancer mortality rates. Multi-target stool DNA tests are innovative screening tools designed to analyze stool samples for genetic and biochemical markers associated with colorectal cancer and precancerous lesions. For instance, in March 2025, Exact Sciences Corp., a US-based molecular diagnostics company, introduced Cologuard Plus, an enhanced at-home colorectal cancer screening test for average-risk adults aged 45 and older. This test incorporates advanced biomarker technology, providing higher sensitivity and specificity compared to its predecessor. It utilizes a refined algorithm to detect DNA mutations and hemoglobin biomarkers, improving the detection of both colorectal cancer and advanced adenomas. The Cologuard Plus test offers a non-invasive and convenient screening option that removes the need for bowel preparation or dietary restrictions, consequently increasing patient adherence to recommended screening guidelines.
Which Players Are Part Of The Competitive Landscape Of The In-vitro Colorectal Cancer Screening Tests Market?
Major companies operating in the in-vitro colorectal cancer screening tests market are Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers, Quest Diagnostics Incorporated, Roche Diagnostics International AG, Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Qiagen N.V., Exact Sciences Corporation, Natera Inc., BGI Genomics Co. Ltd., NeoGenomics Inc., Guardant Health Inc., CellMax Life Inc., Epigenomics AG, Acuamark Diagnostics Inc., Beacon Biomedical Inc., Mainz Biomed NV, Hologic Inc., Danaher Corporation, Agilent Technologies Inc.
Get The Full In-vitro Colorectal Cancer Screening Tests Market Report:
Where Is The In-vitro Colorectal Cancer Screening Tests Market Most Concentrated Geographically?
North America was the largest region in the in-vitro colorectal cancer screening tests market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the in-vitro colorectal cancer screening tests market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized In-vitro Colorectal Cancer Screening Tests Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global In-vitro Colorectal Cancer Screening Tests Market 2026, By The Business Research Company
Antifungals Market Report 2026
https://www.thebusinessresearchcompany.com/report/antifungals-global-market-report
Systemic Aspergillosis And Systemic Candidiasis Market Report
Aspergillosis Treatment Market Report
https://www.thebusinessresearchcompany.com/report/aspergillosis-treatment-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model